LasikPlus, operating as LCA-Vision at the time, sold to the Joffe family in January 2015 for approximately $40 million. The prior owner, PhotoMedex, had paid $106 million for the same asset approximately one year earlier. That's a $66 million write-down on a multi-location refractive chain over a 12-month period, and it remains the cleanest publicly documented data point on how consumer-discretionary refractive platforms perform when the cycle turns against them. Every employee, every clinic, every laser the company owned was worth 62% less in January 2015 than in January 2014. The assets didn't change. The cycle did.

The broader refractive market tells a similar story across a longer timeline. US LASIK procedure volume peaked at approximately 1.4 million procedures per year around 2000 to 2001 according to Market Scope data. Current annual volume sits at roughly half that peak, with 2024 US laser vision correction volumes declining approximately 18 to 20% year over year based on analyst estimates. The average LASIK price has held at approximately $2,246 per eye for 20 years, unadjusted for inflation. The sector continues cycling at lower volume with flat pricing against a consumer base that has roughly doubled in the same period. Capital markets have been trying to figure out what that pattern means for platform valuations in refractive for the last decade, and the answer has been inconsistent. Some refractive platforms have performed well for their sponsors. Others have taken the LasikPlus path.

Why US Ophthalmology Refractive Volumes Keep Falling Without the Sector Disappearing

The consumer-discretionary nature of refractive is the structural explanation. LASIK is an elective procedure paid out of pocket at roughly $2,000 to $5,000 per eye. Unlike cataract, which Medicare covers and demographic aging drives, and unlike retina, which an aging population with diabetic retinopathy and macular degeneration drives, refractive demand correlates almost entirely with consumer confidence and discretionary spending capacity.

The Refractive Surgery Council reported 231,503 procedures in the first half of 2021, an 82% year-over-year increase driven by pandemic-era stimulus and deferred demand. The 2024 decline reversed most of that gain. Historical analysis suggests consumer confidence explains approximately 80% of the variance in refractive surgery volume over time. When rates rise, when recession risk increases, and when discretionary income compresses, refractive volumes fall first and recover last. A refractive platform that signed a 5-year PE hold in 2021 at peak volumes is now three years into that hold at materially lower volumes, with two years left to engineer a liquidity event, and no clear path to the valuation multiple the deal was underwritten on.

The flat pricing story compounds the volume issue. A US worker needed approximately 150 hours of labor to afford bilateral LASIK in 2024, down from approximately 225 hours in 2008. Pricing has held stable in absolute dollars while wages have grown, which should have expanded demand. The ceiling sits at consumer willingness to elect a procedure on a discretionary budget rather than at price, and that willingness tracks macroeconomic conditions more tightly than most refractive operators want to acknowledge.

The EVO ICL Story Inside the Ophthalmology Refractive Market

STAAR Surgical's 2024 net sales were $313.9 million, down from $322.4 million the prior year. ICL sales accounted for $312.5 million, with China representing approximately 51% of total ICL revenue. What the headline decline obscures is that ICL sales excluding China grew 13% year over year, with 17% growth in Q4 2024. US ICL sales grew 22% in Q4 2024, even as the broader US laser vision correction market declined approximately 20%. The substitution is happening inside the refractive category, not outside it.

AECOS surgeon survey data shows EVO ICL running at approximately 13% procedure mix among high-volume US refractive surgeons, compared to 3% in the broader market. Surgeons who do high refractive volume are actively shifting procedure mix toward ICL, particularly for higher myopia patients and patients who fall outside optimal LASIK candidacy. US pricing on EVO ICL runs $3,500 to $8,500 per eye, with most clinics sitting in the $3,800 to $5,000 range. The revenue per eye on an ICL case is meaningfully higher than on a LASIK case, which means a surgeon's total refractive revenue can grow even as their LASIK volume declines, if their practice is positioned to capture the substitution.

In Q1 2025, STAAR's revenue fell 45% year over year to $42.6 million, driven almost entirely by China collapsing to $389,000 in the quarter from much higher prior levels. Alcon announced a $28 per share acquisition bid for STAAR that was immediately contested by activist investors Broadwood Partners at 27.4% ownership and Yunqi Capital at 5.1%. The combined activist stake of more than 32% of STAAR is the structural reason the deal has taken time to resolve. Whatever outcome lands, the contested takeout itself is the signal. A single-product refractive platform with concentrated geographic exposure doesn't get to pick its own liquidity event, and capital markets have spent 18 months pricing that reality.

How SMILE and the Next Ophthalmology Refractive Platform Wave Is Arriving

Zeiss received FDA approval for the VisuMax 800 with SMILE pro software on January 11, 2024, covering myopia with and without astigmatism. The VisuMax 800 creates a corneal lenticule in under 10 seconds using a 2 MHz laser, approximately 5 times faster than the previous generation. Global installed base on VisuMax platforms covers more than 10 million eyes treated by more than 3,000 surgeons across 80 or more countries since the first SMILE approval in 2011.

The US SMILE story is still in early innings. International adoption outpaces US adoption by a wide margin, primarily because the Zeiss VisuMax platform has been the only FDA-approved SMILE laser until very recently, and the capital equipment cost sits above $500,000 per machine. That price point alone has kept most small independent refractive practices from adopting, which means the SMILE market in the US is disproportionately concentrated inside multi-location platforms that can amortize the capital cost across sufficient surgical volume. The practices that already bought a VisuMax are positioned to capture the next growth wave. The practices that didn't are looking at a capital commitment during a cyclical trough.

Premium intraocular lens adoption is the parallel refractive story most capital allocators track alongside LASIK. US premium IOL penetration has grown from 6.8% in 2009 to 7.4% in 2017 to approximately 15 to 22% currently based on Market Scope and Mordor Intelligence analyses. The global IOL market runs approximately $4.47 billion and is projected to reach $6.17 billion by 2030, with the premium segment growing at approximately 9% annually against traditional monofocal growth at 6.2%. Johnson & Johnson launched Tecnis Odyssey in September 2024. Bausch + Lomb received FDA approval for enVista Envy in December 2024. Alcon's PanOptix runs at approximately $2,945 per eye, PanOptix Toric at $3,172. The premium IOL category is effectively converting the aging demographic's cataract procedures into refractive-adjacent out-of-pocket revenue, which is why refractive surgeons increasingly treat premium cataract as part of their refractive practice mix.

What the Ophthalmology Refractive Cycle Is Telling Capital Allocators in 2026

NVISION Eye Centers, founded in 2010 by Dr. Tom Tooma, sold a majority stake to Ontario Teachers' Pension Plan in December 2020. The platform has since completed aggressive M&A including East West Eye Institute, Retina Consultants of Austin in May 2024, and a San Antonio-area ASC in 2023. NVISION currently operates more than 70 practice and ASC locations across 5 states. Pension-backed permanent-hold capital has proven better suited to the refractive cycle than private equity with a forced 5-to-7 year exit, specifically because patient refractive volume moves in multi-year cycles that don't align with typical PE hold periods.

The AI-driven patient acquisition story is the newer differentiator. Clearwave, the patient engagement platform, published a case study on Comprehensive EyeCare Partners showing a 76% increase in premium IOL conversion using AI-powered pre-visit education combined with online scheduling. Zeiss launched the VisioGen AI patient engagement platform at ASCRS in April 2026. The cost of acquiring a refractive patient has been trending upward for a decade, and the platforms that figure out AI-native marketing infrastructure are capturing a disproportionate share of the remaining cyclical demand. Every operator who doesn't upgrade their patient acquisition stack is quietly subsidizing the ones who did.

The capital-allocation question inside refractive has nothing to do with whether the sector is dying, because it isn't. The real question is which platform structures survive the cyclicality, which vintage of acquisition gets caught on the wrong side of a cycle turn, and which acquirers have the patience and the operational model to hold through a trough that might last 3 to 5 years. LasikPlus at $106 million one year and $40 million the next shows one outcome, while NVISION scaling methodically across 5 states under pension-fund patience shows a different one. The structural posture of the buyer determines the outcome when the cycle turns, and in refractive, the cycle always turns. The operators who internalize that reality build for 20-year holds. The ones who don't end up writing the LasikPlus case study for the next generation.

This article is for general educational purposes and is not legal or financial advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you're a practice owner thinking about succession or a physician exploring ownership, we're open to thoughtful conversations.

Contact info@verdira.com | 307-381-3734 | verdira.com